Congrats Margherita on completing her @physicell.bsky.social model investigating the effect of ECM organisation and remodelling and the interplay with chemotaxis on invasion www.biorxiv.org/content/10.1... Great collaboration with @jmetzcar.bsky.social , @mathcancer.bsky.social and Pradeep

Be a part of ‪Endocrine Oncology's ‬special collection celebrating the contributions and leadership of women in Neuroendocrine Tumour (NET) research. Original research, reviews and case reports all welcome! 🔗https://eo.bioscientifica.com/page/Women-in-NETs Submit your proposal: [email protected]

Excited for this @cp-cell.bsky.social article co-led by @fertiglab.bsky.social and Genevieve Stein-O'Brien, on creating a plain language "grammar" to easily write simulation models as virtual laboratories for complex systems like cancer. Fully open access and open source! 🧪 #mathonco #mathbio

A plain text modeling language—a cell behavior hypothesis grammar—to easily build virtual cell models and connect them to data, helping scientists to unlock the hidden dynamics of tissues @cellcellpress.bsky.social @mathcancer.bsky.social www.cell.com/cell/fulltex...

Fantastic work, @mathcancer.bsky.social ! phys.org/news/2025-07...

Due to early detection of #MultipleEndocrineNeoplasia type 2A (MEN2A), made possible by the genetic test, and the high chance of MTC, surgery to remove the thyroid gland is now done in children who carry the gene. ✅Get informed in 11 languages: incalliance.org/net-info-pac... #LetsTalkAboutNETs

Time to rethink our approach to NET grading and use whole slide analysis (WSA) in addition to hotspot analysis (HSA) when assigning tumor grade using Ki-67? It certainly seems so.... @IHC_guy www.modernpathology.org/article/S089...

Wishing you had access to new and updated guidelines on MEN1...? Worry not, this team has you covered. www.sciencedirect.com/science/arti...

Machine learning for model parameterization: mathematical-oncology.org/blog/machine... @hamiscalculated.bsky.social @jmetzcar.bsky.social @stolzbernadette.bsky.social #MathOnco #MachineLearning

PRRT + PARP inhibitors in advanced NETs? To date, no trials have convincingly shown that PRRT + drug X (whatever that may be) is better than PRRT alone. The addition of PARPi seems to add little early toxicity but larger trials needed to show efficacy. jnm.snmjournals.org/content/earl...

Thanks to everyone for a fantastic meeting #SACB2025 @cancersysbio.bsky.social (I sure needed an injection of great science in *these times*) @mathcancer.bsky.social closing out the show...

Improving #neuroendocrine #tumor treatments with mathematical modeling: lessons from other endocrine cancers By John Metzcar et al. @kelines.bsky.social Read it here 👉 https://doi.org/10.1530/EO-24-0025